Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. Thompson JA, et al. Among authors: frigault m. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. J Natl Compr Canc Netw. 2020. PMID: 32135517
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, Maus MV. Choi BD, et al. Among authors: frigault mj. N Engl J Med. 2024 Apr 11;390(14):1290-1298. doi: 10.1056/NEJMoa2314390. Epub 2024 Mar 13. N Engl J Med. 2024. PMID: 38477966
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, Nahed BV, Richardson LG, Scarfò I, Sun J, Wakimoto H, Maus MV, Choi BD. Schmidts A, et al. Neurooncol Adv. 2022 Dec 22;5(1):vdac185. doi: 10.1093/noajnl/vdac185. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36751672 Free PMC article.
Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
Mahmood SS, Riedell PA, Feldman S, George G, Sansoterra SA, Althaus T, Rehman M, Mead E, Liu JE, Devereux RB, Weinsaft JW, Kim J, Balkan L, Barbar T, Lee Chuy K, Harchandani B, Perales MA, Geyer MB, Park JH, Palomba ML, Shouval R, Tomas AA, Shah GL, Yang EH, Gaut DL, Rothberg MV, Horn EM, Leonard JP, Van Besien K, Frigault MJ, Chen Z, Mehrotra B, Neilan TG, Steingart RM. Mahmood SS, et al. Among authors: frigault mj. Eur Heart J. 2023 Jun 9;44(22):2029-2042. doi: 10.1093/eurheartj/ehad117. Eur Heart J. 2023. PMID: 36939851 Free PMC article.
Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T, Johnson PC, Boateng K, Barata A, Traeger L, Nelson AM, Lavoie MW, Holmbeck K, Choe J, Nabily A, Tripathi A, Amonoo HL, Frigault M, El-Jawahri A. Dhawale T, et al. Among authors: frigault m. Transplant Cell Ther. 2024 Apr;30(4):402.e1-402.e12. doi: 10.1016/j.jtct.2024.01.069. Epub 2024 Jan 21. Transplant Cell Ther. 2024. PMID: 38262530
Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Thompson JA, et al. Among authors: frigault m. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013. J Natl Compr Canc Netw. 2019. PMID: 30865922
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.
Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Jacobson CA, et al. Among authors: frigault mj. J Clin Oncol. 2020 Sep 20;38(27):3095-3106. doi: 10.1200/JCO.19.02103. Epub 2020 Jul 15. J Clin Oncol. 2020. PMID: 32667831 Free PMC article.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, Maude SL, McCarthy PL, Mead E, Neelapu SS, Neilan TG, Santomasso BD, Shpall EJ, Teachey DT, Turtle CJ, Whitehead T, Grupp SA. Maus MV, et al. J Immunother Cancer. 2020 Dec;8(2):e001511. doi: 10.1136/jitc-2020-001511. J Immunother Cancer. 2020. PMID: 33335028 Free PMC article.
127 results